April 2026 once again confirmed our strong growth trajectory in the ophthalmology market.
Maintaining the #1 position in dry eye treatment, Sona-Exim also achieved the #3 position among all companies in the overall ophthalmology market in Ukraine.
While the category declined by 4% in value versus April 2025 and by 3% versus March 2026, growth in this environment is no longer about momentum. It reflects strategy, execution quality, and the ability to remain relevant to healthcare professionals every single day.
While the market was declining, Sona-Exim demonstrated:
- +19% sales growth
- EI 124
- continued strengthening of market share in one of the most competitive therapeutic categories
These results reflect much more than commercial performance.
They reflect the strength of long-term partnerships, the quality of everyday execution, the trust of ophthalmologists and pharmacy professionals, and the ability of teams to consistently deliver in a highly dynamic healthcare environment.
Ophthalmology today is one of the fastest-evolving categories in pharma. Expectations around treatment quality, accessibility, physician support, and patient adherence continue to grow alongside increasing competition and market pressure.
